dudette wrote:Thanks muchly for sharing!
Could you briefly expand on the limited safety window, please? Is it because all cells have/express CD47 and the trial drug will also go after the healthy cells?
KElizabeth wrote:I'm confused about the use of Cetuximab with KRAS mutant CRC in this trial. Is the thought that the CD47 will circumvent the process that causes the poor prognosis that is associated with the use of Cetuximab with KRAS?
DK37 wrote: CD47 is a "don't eat me" signal sent to macrophages - the drug blocks it from doing this. An issue with anti-CD47 drugs is a small safety window but they are working to address that.
CD47 made a huge splash in the scientific world a few years ago with its preclinical data. People have been anxiously watching to see how it behaves in the clinic.
CD47 Studies Take Immunotherapy in New Direction
October 31, 2016
(...) The dominant strategy thus far has been to activate T cells, the central mediators of the adaptive immune response. This approach is antigen specific, involves memory recall, and could in theory have long-lasting therapeutic benefit.
Yet there are 2 arms to the immune system that act in concert with one another and evidence is building that the second arm—the innate immune response—is also likely to be important.
As a result, researchers and pharmaceutical companies, seeking to carve out new niches in the immuno-oncology field, are looking to the major player in the innate immune response: the macrophages.
A particularly promising therapeutic target in this area is the CD47 protein, dubbed the “don’t eat me” signal for its role in inhibiting the phagocytic activity of macrophages and seemingly exploited by cancer cells to make them appear as normal cells to the innate immune response. -
Full article: here
James Allison Says Rational Combinations Key to Immunotherapy Success in "Cold" Tumors
Oct 31, 2016
(...) “There is enough progress being made across the board that I think we can start thinking about some of the colder tumors responding if we just keep studying and making rational combination decisions,” said Allison, professor and chair of Immunology at MD Anderson Cancer Center. “As we understand this better, we can rationally put two things together that won’t just duplicate or cancel each other out, but will do different things that can at least be additive, if not synergistic.”
Full article: here